Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Common Equity for 6 consecutive years, with $122.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 51.7% to $122.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.2 million through Dec 2025, down 51.7% year-over-year, with the annual reading at $122.2 million for FY2025, 51.7% down from the prior year.
  • Common Equity for Q4 2025 was $122.2 million at Caribou Biosciences, down from $141.8 million in the prior quarter.
  • The five-year high for Common Equity was $404.4 million in Q3 2021, with the low at -$47.7 million in Q2 2021.
  • Average Common Equity over 5 years is $260.2 million, with a median of $291.0 million recorded in 2022.
  • Peak annual rise in Common Equity hit 3707.18% in 2021, while the deepest fall reached 1599.48% in 2021.
  • Over 5 years, Common Equity stood at $387.8 million in 2021, then decreased by 22.42% to $300.9 million in 2022, then rose by 22.44% to $368.4 million in 2023, then plummeted by 31.34% to $253.0 million in 2024, then tumbled by 51.7% to $122.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $122.2 million, $141.8 million, and $166.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.